Global Neurology Academy

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Who’s Missing from Multiple Sclerosis Research?
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
- Ashley Baker, MSN, PMHNP
- Ruth Ann Marrie, MD, PhD
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Multiple Sclerosis Without Borders: Taking a Global View
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
- Andrew Wilner, MD, FACP, FAAN
- Victor Rivera, MD
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
CME/CE In-Person & Virtual Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
March 23, 2026
Boston, Massachusetts
1.00 credit Learn more

Medical News

Medical News
CAR‑Astrocyte Therapy: Single‑Injection Amyloid Clearance Reported in Mice
03/09/2026
Read more
Medical News
Experts: No Robust Evidence of ADHD Overdiagnosis in the UK
03/09/2026
Read more
Medical News
New Evidence on Weekday Sleep Duration and eGDR
03/05/2026
Read more
Medical News
Cortical Pyramidal Neuron Dysfunction in TH‑KO Mice and L‑Dopa–Mediated Restoration
03/04/2026
Read more

See more news

CME/CE

CME/CE In-Person Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
Boston, Massachusetts
1.00 credit Learn more
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
CME/CE Virtual Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
12:30 PM - 01:30 PM EDT
1.00 credit Learn more
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
CME/CE
Advancing gMG Clinical Decisions: Diagnosing Early, Treating Smarter, and Caring Holistically – A Case-Based Treatment Approach
0.25 credits
- Christyn Edmundson, MD
- Neelam Goyal, MD
0.25 credits

Clinical Practice

The Burden of Cognitive Dysfunction in Multiple Sclerosis
The Burden of Cognitive Dysfunction in Multiple Sclerosis
NeuroFrontiers
The Burden of Cognitive Dysfunction in Multiple Sclerosis
- Christopher Lock, MD
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Understanding Accelerated Biological Aging in Pediatric MS
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
- Jennifer Yang, MD
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley

Programs

Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
- Ryan Quigley
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
- Alexandria May, PharmD, BCPS
- Apurva Bhatt, MD
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiers
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
Iron Deposition and Cognitive Fatigue in Multiple Sclerosis
NeuroFrontiers
Iron Deposition and Cognitive Fatigue in Multiple Sclerosis